Abstract: There is provided a protein stabilizer containing a compound represented by Formula (1) as an active ingredient. The protein stabilizer is capable of stabilizing a protein in a solution state for a long period of time without affecting an assay system, the protein being not limited to enzymes, labeling substances such as fluorescent substances and chemiluminescent substances, and assay target substances. There is also provided a protein stabilization method containing making the protein coexist with the compound represented by Formula (1) in a water-containing solution. In Formula (1), X is a hydrogen atom or a methyl group, and n is an integer of 3 to 17.

Abstract: Provided is a volatile oil for cosmetics, which has excellent volatility, hair care properties and skin care properties. The volatile oil for cosmetics according to the present invention comprises a paraffin mixture, wherein the paraffin mixture contains an isoparaffin having 12 to 16 carbon atoms, has a boiling point ranging from 185 to 215° C. and has a 2,2,4,6,6-pentamethylheptane content of less than 10 mass %. The volatile oil for cosmetics according to the present invention can be used for, for example, a hair cosmetic and an external preparation for the skin.

Abstract: [Object] To provide a phosphorylcholine group-containing compound capable of producing a phosphorylcholine complex, and the phosphorylcholine complex, the phosphorylcholine complex being easily manufactured and suitable for use as a phosphorylcholine antigen. [Solving Means] There are provided a phosphorylcholine group-containing compound having a structure represented by the following formula (1), and a phosphorylcholine-protein complex having a structure in which the phosphorylcholine group-containing compound and an amino acid amine site of a protein are amide bonded. (X represents a hydrogen atom, a monovalent cation residue, or a hydroxysuccinimide group).

Abstract: A method for producing a cationic lipid, wherein a cationic lipid represented by formula (1) is mixed with a tetraalkylammonium salt having X? in an organic solvent, and a filtrate obtained by separating a tetraalkylammonium iodide deposited by filtration is concentrated to deposit a tetraalkylammonium iodide, thereby obtaining a cationic lipid represented by formula (2): wherein R1 to R5 and X? are as defined herein.

Abstract: An object is to provide a method of manufacturing a vessel for embryoid body formation excellent in formability of an embryoid body and suitable for optical observation.

Abstract: The invention provides a method for the prophylaxis or treatment of hepatitis C in a mammal with a peptide-bound liposome wherein the peptide contains a partial amino acid sequence having a length of not less than 9 amino acids in the amino acid sequence of hepatitis C virus NS3 protein, has a length of 9 to 11 amino acids, and is capable of inducing cytotoxic T lymphocytes; the liposome contains a phospholipid containing an acyl group having 14 to 24 carbon atoms and one unsaturated bond or a hydrocarbon group having 14 to 24 carbon atoms and one unsaturated bond, and a liposome stabilizer; and the peptide is bound to the surface of the liposome. The invention also provides a cytotoxic T lymphocyte activator containing the peptide-bound liposome, as well as a hepatitis C virus vaccine.

Abstract: An ethylene-vinyl acetate copolymer resin composition includes: an (A) ethylene-vinyl acetate copolymer; a (B) vinyl copolymer; and a (C) organic peroxide. The (B) vinyl copolymer and the (C) organic peroxide are impregnated in the (A) ethylene-vinyl acetate copolymer. The (A) ethylene-vinyl acetate copolymer includes 1 to 20 wt % of a vinyl acetate. The (B) vinyl copolymer is formed of a (b-1) styrene, (b-2) at least one of acrylonitrile and glycidyl methacrylate, a (b-3) t-butylperoxymethacryloyloxyethyl carbonate, and a (b-4) polymerization initiator. A content of the (C) organic peroxide is 0.1 to 3 parts by weight relative to 100 parts by weight of the (A) ethylene-vinyl acetate copolymer.

Abstract: A surface physical property modifier composition includes (A) a wax, (B) a vinyl (co)polymer, and (C) an aliphatic hydrocarbon having a carbon number of 5 to 14. Component (A) is set to be at least one selected from the group consisting of (a1) paraffin wax, (a2) microcrystalline wax, (a3) Fischer-Tropsch wax, and (a4) polyethylene wax, and component (B) is produced from at least one of (b1) a (meth)acrylonitrile, (b2) a (meth)acrylic acid having a carbon number of 1 to 4, (b3) a hydroxyethyl (meth)acrylate or hydroxypropyl (meth)acrylate, (b4) styrene, and (b5) predetermined (meth)acrylic acid alkyl esters. Component (A) is 50 to 98 parts by mass relative to 100 parts by mass of the total of (A) and (B), and component (C) is 0.001 to 1 percent by mass relative to the total amount of (A).

Abstract: An antibody-drug conjugate having a cyclic benzylidene acetal linker represented by formula (1) or formula (2), wherein Y is an antibody; D is a drug; R1 and R6 are each independently a hydrogen atom or a hydrocarbon group; R2, R3, R4 and R5 are each independently an electron-withdrawing or electron-donating substituent or a hydrogen atom; s is 1 or 2, t is 0 or 1, and s+t is 1 or 2; w is an integer of 1 to 20; and Z1 and Z2 are each independently a selected divalent spacer:

Abstract: An oral composition for reducing dentinal hypersensitivity according to the present invention comprises a phosphorylcholine-containing polymer as an active ingredient. A general consumer can use the oral composition routinely in various forms. The oral composition is brought into contact with an oral cavity of a user to reduce the dentinal hypersensitivity.

Abstract: A method of producing a medical polyoxypropylene polymer and a polyoxypropylene/polyoxyethylene block copolymer including (A) adding to a polyoxypropylene polymer which is obtained by ring-opening polymerization of propylene oxide to a starting substance having an active hydrogen reacting with the propylene oxide and contains allyl ether as an impurity, a tertiary alkoxide of alkali metal in an excess amount based on a molar number of the active hydrogen of the starting substance and heat treating at 115° C. or less to isomerize the allyl ether to propenyl ether; and (B) adding a mineral acid to the product obtained in step (A) to adjust pH to 4 or less and treating at 70° C. or less to hydrolyze the propenyl ether. Also disclosed is a method of producing a medical polyoxypropylene/polyoxyethylene block copolymer which includes performing ring-opening polymerization of ethylene oxide to the polyoxypropylene polymer obtained above.

Abstract: The invention provides a cationic lipid capable of achieving higher intracellular delivery efficiency than conventional cationic lipids, when used as a lipid membrane structure which is a carrier for delivering functional nucleic acid. The cationic lipid is represented by the formula (1): wherein each symbol is as defined herein.

Abstract: A method for producing a cationic lipid, wherein a cationic lipid represented by formula (1) is mixed with a tetraalkylammonium salt having X? in an organic solvent, and a filtrate obtained by separating a tetraalkylammonium iodide deposited by filtration is concentrated to deposit a tetraalkylammonium iodide, thereby obtaining a cationic lipid represented by formula (2): wherein R1 to R5 and X? are as defined herein.

Abstract: A protein adsorption inhibitor includes a compound of Formula (1) as an active ingredient. The protein adsorption inhibitor is capable of highly inhibiting non-specific adsorption of a protein such as an antibody or an enzyme to a surface of a base body such as an immune reaction vessel or an assay instrument. Also provided is a coating layer-formed base body having a coating layer containing the protein adsorption inhibitor on the base body. The coating layer-formed base body has an excellent protein adsorption-inhibiting function. A method for inhibiting the adsorption of the protein to the base body is provided. The method includes forming the coating layer containing the protein adsorption inhibitor on the surface of the base body: wherein, X is a hydrogen atom or a methyl group and n is an integer of 9 to 15.

Abstract: The present invention provides a paraffin mixture that is suitable for use as cosmetics and cleansing oil for skin and hair and has excellent volatility. The paraffin mixture according to the present invention is a mixture that contains isoparaffin having a carbon number of 12 to 16, and the mixture has a boiling point range of 185° C. to 215° C. and has the content of 2,2,4,6,6-pentamethylheptane at less than 10 mass %.

Abstract: There is provided a protein stabilizer containing a compound represented by Formula (1) as an active ingredient. The protein stabilizer is capable of stabilizing a protein in a solution state for a long period of time without affecting an assay system, the protein being not limited to enzymes, labeling substances such as fluorescent substances and chemiluminescent substances, and assay target substances. There is also provided a protein stabilization method containing making the protein coexist with the compound represented by Formula (1) in a water-containing solution. In Formula (1), X is a hydrogen atom or a methyl group, and n is an integer of 3 to 17.

Abstract: The present invention relates to a compound represented by the formula (1) wherein Xa and Xb are each independently X1 or X2; s is 1 or 2, R4 is an alkyl group having 1-6 carbon atoms, na and nb are each independently 0 or 1, R1a and R1b are each independently an alkylene group having 1-6 carbon atoms, R2a and R2b are each independently an alkylene group having 1-6 carbon atoms, Ya and Yb are each independently an ester bond, an amide bond, a carbamate bond, an ether bond or a urea bond, and R3a and R3b are each independently a sterol residue, a liposoluble vitamin residue or an aliphatic hydrocarbon group having 12-22 carbon atoms, and use thereof.

Abstract: A wireless detonator is provided with: a detonation part; a control part for igniting the detonation part, the control part being connected to the detonation part; a tube for accommodating the detonation part and the control part; and a detonation-side antenna used by the control part for wireless communication and capable of being used for sending and receiving without separately having a transmission-only antenna and a reception-only antenna; the detonation-side antenna being a soft magnetic body coil antenna, and the control part receiving, via the detonation-side antenna, a transmission signal at an operating frequency of 100-500 KHz.

Abstract: The invention provides a cell mobilizing agent capable of efficiently and continuously accumulating cells involved in tissue repair. In particular, the cell mobilizing agent contains a lysophospholipid introduced with retinoic acid represented by the formula (1) and/or the formula (2) or a physiologically acceptable salt thereof as an active ingredient: wherein R1 and R2 are each a retinoyl group or hydrogen and are not the same.

Abstract: The present invention provides a polymer compound that can be expected to inhibit activation of a coagulation system, a complement system or a platelet system when brought into contact with in vivo tissue and/or blood since the compound is capable of containing intermediate water, and a composition and a device using the same. This problem is solved by a polymer compound containing a repeating unit represented by general formula (A), and used in contact with in vivo tissue and/or blood, in which in a process in which the polymer compound caused to contain water in a prescribed water content is cooled to ?100° C. and thereafter heated at a temperature rise rate of 5.0° C./min, a temperature region where exothermicity occurs is present in the range of ?80° C. or more and ?25° C. or less, and a temperature region where endothermicity occurs is present in the range of ?25° C. or more and lower than 0° C.: wherein R represents a hydrocarbon group having 1 to 20 carbon atoms.